The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1599
June 1, 2020
View Complete Issue         Table of Contents 2019 
Issue 1599
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Respiratory Depression with Gabapentinoids
June 1, 2020 (Issue: 1599)
The FDA has required new warnings in the labels of gabapentin (Neurontin, and others) and pregabalin (Lyrica, Lyrica CR, and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1599
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.